FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1540221646> ?p ?o ?g. }

• W1540221646 endingPage "72" @default.
• W1540221646 startingPage "64" @default.
• W1540221646 abstract "The Review of Diabetic Studies,2008,5,2,73-94.DOI:10.1900/RDS.2008.5.73Published:August 2008Type:Review Article Authors:Richard E Pratley, and Matthew Gilbert Author(s) affiliations:Richard E. Pratley and Matthew Gilbert Diabetes and Metabolism Translational Medicine Unit, University of Vermont College of Medicine, Burlington, VT, USA. Abstract:Until recently, the pathogenesis of type 2 diabetes mellitus (T2DM) has been conceptualized in terms of the predominant defects in insulin secretion and insulin action. It is now recognized that abnormalities in other hormones also contribute to the development of hyperglycemia. For example, the incretin effect, mediated by glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP), is attenuated in T2DM. Intravenous administration of GLP-1 ameliorates hyperglycemia in patients with T2DM, but an extremely short half-life limits its utility as a therapeutic agent. Strategies to leverage the beneficial effects of GLP-1 include GLP-1 receptor agonists or analogs or dipeptidyl peptidase-4 (DPP-4) inhibitors—agents that act by slowing the inactivation of endogenous GLP-1 and GIP. The GLP-1 agonist exenatide has been shown to improve HbA1c and decrease body weight. However, exenatide is limited by its relatively short pharmacologic half-life, various gastrointestinal (GI) side effects, and the development of antibodies. Studies of a long-acting exenatide formulation suggest that it has improved efficacy and also promotes weight loss. Another prospect is liraglutide, a once-daily human GLP-1 analog. In phase 2 studies, liraglutide lowered HbA1c by up to 1.7% and weight by approximately 3 kg, with apparently fewer GI side effects than exenatide. DPP-4 inhibitors such as sitagliptin and vildagliptin result in clinically significant reductions in HbA1c, and are weight neutral with few GI side effects. This review will provide an overview of current and emerging agents that augment the incretin system with a focus on the role of GLP-1 receptor agonists and DPP-4 inhibitors. Keywords:DPP-4, Exenatide, GLP-1 analog, Incretin, Liraglutide, Sitagliptin, Type 2 diabetes, VildagliptinView:PDF (2.53 MB)" @default.
• W1540221646 created "2016-06-24" @default.
• W1540221646 creator A5001935591 @default.
• W1540221646 creator A5023291432 @default.
• W1540221646 creator A5023859731 @default.
• W1540221646 creator A5075197576 @default.
• W1540221646 creator A5088780864 @default.
• W1540221646 date "2008-01-01" @default.
• W1540221646 modified "2023-09-25" @default.
• W1540221646 title "Genetic Basis of Type 1 Diabetes: Similarities and Differences between East and West" @default.
• W1540221646 cites W136910319 @default.
• W1540221646 cites W1519521580 @default.
• W1540221646 cites W1520109974 @default.
• W1540221646 cites W1967744736 @default.
• W1540221646 cites W1971159424 @default.
• W1540221646 cites W1971252213 @default.
• W1540221646 cites W1972406690 @default.
• W1540221646 cites W1973154630 @default.
• W1540221646 cites W1987661892 @default.
• W1540221646 cites W1987677365 @default.
• W1540221646 cites W2014077667 @default.
• W1540221646 cites W2015941944 @default.
• W1540221646 cites W2016185852 @default.
• W1540221646 cites W2026468137 @default.
• W1540221646 cites W2031539362 @default.
• W1540221646 cites W2031755982 @default.
• W1540221646 cites W2034957838 @default.
• W1540221646 cites W2044624255 @default.
• W1540221646 cites W2049740824 @default.
• W1540221646 cites W2066874799 @default.
• W1540221646 cites W2071345208 @default.
• W1540221646 cites W2071985067 @default.
• W1540221646 cites W2083545100 @default.
• W1540221646 cites W2084215480 @default.
• W1540221646 cites W2084325574 @default.
• W1540221646 cites W2084609878 @default.
• W1540221646 cites W2087265576 @default.
• W1540221646 cites W2092577213 @default.
• W1540221646 cites W2095902064 @default.
• W1540221646 cites W2101070171 @default.
• W1540221646 cites W2102266262 @default.
• W1540221646 cites W2104236690 @default.
• W1540221646 cites W2115209313 @default.
• W1540221646 cites W2122825774 @default.
• W1540221646 cites W2127591233 @default.
• W1540221646 cites W2131889332 @default.
• W1540221646 cites W2134783591 @default.
• W1540221646 cites W2169478776 @default.
• W1540221646 cites W2299176942 @default.
• W1540221646 cites W3140856393 @default.
• W1540221646 doi "https://doi.org/10.1900/rds.2008.5.64" @default.
• W1540221646 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2556443" @default.
• W1540221646 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18795209" @default.
• W1540221646 hasPublicationYear "2008" @default.
• W1540221646 type Work @default.
• W1540221646 sameAs 1540221646 @default.
• W1540221646 citedByCount "31" @default.
• W1540221646 countsByYear W15402216462012 @default.
• W1540221646 countsByYear W15402216462013 @default.
• W1540221646 countsByYear W15402216462014 @default.
• W1540221646 countsByYear W15402216462015 @default.
• W1540221646 countsByYear W15402216462016 @default.
• W1540221646 countsByYear W15402216462017 @default.
• W1540221646 countsByYear W15402216462018 @default.
• W1540221646 countsByYear W15402216462019 @default.
• W1540221646 countsByYear W15402216462020 @default.
• W1540221646 countsByYear W15402216462021 @default.
• W1540221646 countsByYear W15402216462022 @default.
• W1540221646 crossrefType "journal-article" @default.
• W1540221646 hasAuthorship W1540221646A5001935591 @default.
• W1540221646 hasAuthorship W1540221646A5023291432 @default.
• W1540221646 hasAuthorship W1540221646A5023859731 @default.
• W1540221646 hasAuthorship W1540221646A5075197576 @default.
• W1540221646 hasAuthorship W1540221646A5088780864 @default.
• W1540221646 hasBestOaLocation W15402216462 @default.
• W1540221646 hasConcept C126322002 @default.
• W1540221646 hasConcept C134018914 @default.
• W1540221646 hasConcept C170493617 @default.
• W1540221646 hasConcept C181199279 @default.
• W1540221646 hasConcept C185592680 @default.
• W1540221646 hasConcept C2776398474 @default.
• W1540221646 hasConcept C2777180221 @default.
• W1540221646 hasConcept C2778881409 @default.
• W1540221646 hasConcept C2778938600 @default.
• W1540221646 hasConcept C2779306644 @default.
• W1540221646 hasConcept C2780533449 @default.
• W1540221646 hasConcept C2781308992 @default.
• W1540221646 hasConcept C2781469919 @default.
• W1540221646 hasConcept C2910068830 @default.
• W1540221646 hasConcept C511355011 @default.
• W1540221646 hasConcept C544821477 @default.
• W1540221646 hasConcept C55493867 @default.
• W1540221646 hasConcept C555293320 @default.
• W1540221646 hasConcept C71924100 @default.
• W1540221646 hasConcept C98274493 @default.
• W1540221646 hasConceptScore W1540221646C126322002 @default.
• W1540221646 hasConceptScore W1540221646C134018914 @default.
• W1540221646 hasConceptScore W1540221646C170493617 @default.

• next